News | Ventricular Assist Devices (VAD) | July 05, 2016

HeartWare Extends Recall of Ventricular Assist Device to Include Batteries

Company indicated batteries may lose power prematurely, causing the pump to cease functioning

HeartWare, HVAD, batteries recall

July 5, 2016 — HeartWare Inc. announced a recall of the batteries used on the HeartWare Ventricular Assist Device (HVAD) because the batteries may lose power prematurely due to faulty cells.

The company said if the HVAD system is not connected to an additional power source shortly after the system sounds an alarm indicating a low battery level, the pump will stop working and the patient may experience serious adverse health consequences, including death.

The recall includes 18,631 model 1650 units in the United States, including Washington, D.C., including devices manufactured between May 19, 2013 and July 1, 2015, and distributed between May 21, 2013 and July 31, 2015. Affected serial numbers include BAT000001 to BAT199999.

The HVAD helps deliver blood from the heart to the rest of the body. It is used in patients who are at risk of death from end-stage left ventricular heart failure and who are waiting for a heart transplant. The system includes a pump implanted in the space around the heart (pericardium) and a controller that controls the speed and function of the pump.

HeartWare sent an "Urgent: Medical Device Recall" letter to affected customers on Jan. 7, 2016. The letter instructed customers to:

  • Complete and return the acknowledgement form attached with the letter
  • Identify and quarantine affected batteries under patients’ possession and in hospitals
  • Arrange an appointment with a qualified representative for replacement batteries with improved cells
  • Return the affected products to HeartWare Inc. along with the completion form attached with the letter
  • Forward the notice to third affected customers

For more information: www.heartware.com


Related Content

News | Heart Failure

May 28, 2026 — Coredio has announced that the U.S. Food and Drug Administration (FDA) has granted its Cardiac ...

Home May 28, 2026
Home
News | Heart Failure

May 10, 2026 — WhiteSwell has announced primary results from the DELTA-HF feasibility clinical trial evaluating the eLym ...

Home May 21, 2026
Home
Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
Subscribe Now